No significant effect was seen for waist circumference ( WC ) and body fat percent .
A non-linear dose-response association was seen between l-carnitine supplementation and body weight reduction ( P < 0.001 ) suggesting that ingestion of 2000 mg l-carnitine per day provides the maximum effect in adults .
This association was not seen for BMI , WC and body fat percent .
CONCLUSIONS l-carnitine supplementation provides a modest reducing effect on body weight , BMI and fat mass , especially among adults with overweight/obesity
BACKGROUND AND AIM Clinical evidence which investigated the effects of l-carnitine , a vitamin-like substance , on weight loss had led to inconsistent results .
This study therefore aim ed to examine the effect of l-carnitine supplementation on body weight and composition by including the maximum number of r and omized controlled trials ( RCTs ) and to conduct a dose-response analysis , for the first time .
L-carnitine supplementation decreases the left ventricular mass in patients undergoing hemodialysis.
BACKGROUND Patients on long-term hemodialysis become deficient in carnitine and are frequently treated with carnitine supplementation to offset their renal anemia , lipid abnormality and cardiac dysfunction . The therapeutic value of carnitine supplementation on left ventricular hypertrophy ( LVH ) in patients with normal cardiac systolic function remains uncertain . METHODS AND RESULTS The cardiac morphology and function of 10 patients given 10 mg/kg of L-carnitine orally  , immediately after hemodialysis sessions  3 times per week for a 12-month period were compared with 10 untreated control patients  . Using echocardiography , left ventricular fractional shortening ( LVFS ) and left ventricular mass index ( LVMI ) were measured before and after the study period . As a result , amounts of serum-free carnitine increased from 28.4+/-4.7 to 58.5+/-12.1 micromol/L. The LVMI decreased significantly from 151.8+/-21.2 to 134.0+/-16.0 g/m(2 ) in treated patients ( p<0.01 ) , yet the LVMI in untreated control patients did not change significantly ( ie , from 153.3+/-28.2 to 167.1+/-43.1 g/m(2 ) ) . However , LVFS values remained unchanged in both groups . Although L-carnitine promoted a 31 % reduction in erythropoietin requirements , hematocrit and blood pressure did not change during the study period . CONCLUSIONS Supplementation with L-carnitine induced regression of LVH in patients on hemodialysis , even for those with normal systolic function
No significant effect was seen for waist circumference ( WC ) and body fat percent .
A non-linear dose-response association was seen between l-carnitine supplementation and body weight reduction ( P < 0.001 ) suggesting that ingestion of 2000 mg l-carnitine per day provides the maximum effect in adults .
This association was not seen for BMI , WC and body fat percent .
CONCLUSIONS l-carnitine supplementation provides a modest reducing effect on body weight , BMI and fat mass , especially among adults with overweight/obesity
BACKGROUND AND AIM Clinical evidence which investigated the effects of l-carnitine , a vitamin-like substance , on weight loss had led to inconsistent results .
This study therefore aim ed to examine the effect of l-carnitine supplementation on body weight and composition by including the maximum number of r and omized controlled trials ( RCTs ) and to conduct a dose-response analysis , for the first time .